Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …

Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …

This document provides clinical recommendations for the management of severe asthma.
Comprehensive evidence syntheses, including meta-analyses, were performed to …

Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Background No consensus exists on how to reduce oral corticosteroids after the initiation of
biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a …

Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …

Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …